Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast

Natera, Inc.

2024-Q3 EPS reported -$1.12 revenue$1,220,850,000

Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.
Oncology tests 137,100 (+54.4%); total tests processed 775,800 (+23.9%).
Net loss narrowed to $31.6M ($0.26/sh) from $109M ($0.95/sh); positive cash flow $34.5M.
2024 guidance raised: revenue $1.61-1.64B, gross margin 58-61%, net cash inflow $50-75M.
Cash $922.3M; all convertible notes redeemed/converted on Oct 11, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.